本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载，触及重大违法强制 退市情形。公司股票已于 2025 年 7 月 14 日起被叠加实施重大违法类强 制退市风险警示。 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司 股票将被终止上市。根据《上海证券交易所股票上市规则》第 9.5.7 条、 第 9.5.8 条，如公司后续收到行政处罚决定书，显示公司触及重大违法 类强制退市情形，公司将申请停牌，并及时披露有关内容。上海证券交 易所将在停牌之日起的 5 个交易日内，向公司发出拟终止股票上市的事 先告知书，后续将根据《上海证券交易所股票上市规则》的相关规定， 作出是否终止公司股票上 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600200 证券简称：*ST苏吴（维权） 公告编号：临2025-113 江苏吴中医药发展股份有限公司 关于公司控股孙公司重大仲裁进展的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实、准确和完整承担法律责任。 重要内容提示： ● Regen Biotech, Inc.就其与达透医疗之间的经销合同纠纷事宜提出的反请求，仲裁院已受理，尚未开庭 审理。 2025年9月23日，达透医疗收到仲裁院反请求受理通知[（2025）深国仲涉外受8781号-6]，仲裁院决定受 理Regen Biotech, Inc.就其与达透医疗之间的经销合同纠纷事宜提出的反请求申请。 反请求主要内容： 1、裁决确认达透公司在中国大陆区域（不含港澳台地区）的AestheFill产品的独家代理权终止； 2、裁决确认作为《关于AestheFill独家代理权转让协议》附件的EXCLUSIVE DISTRIBUTORSHIP AGREEMENT (Fourth Revised Agreement)及其2021年1月15日和2021年12 ...

Core Viewpoint - New Oxygen has launched a new product, Miracle Youth 3.0, priced at 2999 yuan, which is considered the lowest price in the domestic "youth needle" market, significantly lower than the market average of 12800 yuan per injection [2][3] Group 1: Product Launch and Pricing Strategy - New Oxygen's new product, Miracle Youth 3.0, is a customized version of the "youth needle" developed in collaboration with Jiangsu Xihong Biological Pharmaceutical Co., Ltd [2] - The average market price for "youth needles" in China is around 12800 yuan, while prices in neighboring countries can be as low as one-third of that [3] - New Oxygen's pricing strategy aims to lower its own profit margins to make the product more accessible, without compromising on quality or service [3] Group 2: Market Dynamics and Competition - The "youth needle" market in China is experiencing significant competition, highlighted by the ongoing dispute between Jiangsu Wuzhong and Aimeike over distribution rights [5][6] - As of 2023, the market size for micro-injection products in China reached 212 billion yuan, with projections to grow to 653 billion yuan by 2028, reflecting a compound annual growth rate of 25.3% [4] - The regenerative anti-aging segment is the fastest-growing sub-market, with a compound annual growth rate of 38.2% [4] Group 3: Regulatory and Legal Issues - Jiangsu Wuzhong has faced challenges regarding the exclusive distribution agreement for the "youth needle" product, with Aimeike's acquisition of Regen leading to a legal dispute [5][6] - The Shenzhen International Arbitration Court has issued temporary measures regarding the sales of the product in question, indicating ongoing legal complexities in the market [6][7] - Industry experts suggest that the commercial disputes reflect the significant potential and allure of the "youth needle" market, with expectations for further price reductions as more products gain approval [7]

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-114 江苏吴中医药发展股份有限公司 关于股票交易暨退市风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要风险提示： 一、公司存在重大违法退市风险 2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先告知书》（处 罚字〔2025〕58 号），具体内容详见公司于 2025 年 7 月 14 日披露的《关于收 江苏吴中医药发展股份有限公司（以下简称"公司"）股票存在多重退 市风险，敬请广大投资者理性投资、审慎决策，切勿盲目跟风炒作，避 免因公司股价波动造成投资损失。 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《行政处罚事先告知书》（处罚字〔2025〕58 号）， 认定公司虚增营业收入、营业成本和利润，2020-2023 年年度报告存在 虚假记载，触及重大违法强制退市情形。 公司目前存在控股股东大额资金占用尚未解决、控股股东所持股份被全 部冻结、医美产品独家代理权仲裁结果存在不确 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-113 江苏吴中医药发展股份有限公司 关于公司控股孙公司重大仲裁进展的公告 2025 年 9 月 23 日，达透医疗收到仲裁院反请求受理通知[（2025）深国仲 涉外受 8781 号-6]，仲裁院决定受理 Regen Biotech, Inc.就其与达透医疗之间 的经销合同纠纷事宜提出的反请求申请。 反请求主要内容： 1、裁决确认达透公司在中国大陆区域（不含港澳台地区）的 AestheFill 产品的独家代理权终止； 2、裁决确认作为《关于 AestheFill 独家代理权转让协议》附件的 EXCLUSIVE DISTRIBUTORSHIP AGREEMENT (Fourth Revised Agreement)及其 2021 年 1 月 15 日和 2021 年 12 月 22 日修订案解除； 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 一、仲裁基本情况 1、江苏吴中医药发展股份有限公司(以下简称"公司")控股孙公司达透医 疗器械（上海）有 ...

Summary of Key Points Core Viewpoint - The average stock price of A-shares is 13.44 yuan, with 32 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.44 yuan [1] Group 1: Market Performance - As of September 23, the Shanghai Composite Index closed at 3821.83 points, with a notable presence of low-priced stocks in the market [1] - Among the low-priced stocks, 5 out of 32 increased in price, with Yongtai Energy rising by 6.17%, *ST Yuan Cheng by 2.31%, and Zitian Tui by 2.17% [1] - Conversely, 26 stocks declined, with Yabo Co. falling by 6.01%, Beichen Industry by 5.94%, and Yatai Group by 5.39% [1] Group 2: Low-Priced Stocks Overview - The list of low-priced stocks includes 14 ST stocks, accounting for 43.75% of those priced below 2 yuan [1] - The lowest priced stock is *ST Gao Hong at 0.44 yuan, followed by Zitian Tui at 0.47 yuan and *ST Su Wu at 0.90 yuan [1] - The table of low-priced stocks shows various metrics such as daily price changes, turnover rates, and industry classifications, indicating a diverse range of sectors represented [1][2]

Policy Developments - The Central Commission for Discipline Inspection and the National Supervisory Commission are intensifying efforts to rectify issues in the pharmaceutical sector, focusing on eliminating practices such as medical staff accepting "red envelopes" and improper benefits through academic exchanges [1] Drug and Device Approvals - YKYY013 injection from Yuyuan Pharmaceutical has received FDA approval for clinical trials aimed at treating chronic hepatitis B virus infection, which utilizes a dual-stranded siRNA mechanism to silence the virus [2] - *ST Suwu's hydrochloride lincomycin injection has passed the consistency evaluation for generic drugs, receiving approval from the National Medical Products Administration [3] - Tianjin Pharmaceutical's recombinant human urokinase (Puyouke) has been granted approval for a new indication for thrombolytic treatment of acute ischemic stroke, expanding its product line in the neurological field [4] Capital Market - Lepu Medical has entered into a strategic cooperation agreement with Hanhai Information Technology, aiming to enhance its medical aesthetics business through shared resources and a comprehensive sales network [5] Industry Events - The National Medical Insurance Administration has published the first batch of typical cases involving violations by designated medical institutions, highlighting issues such as falsifying medical records and duplicate charges [6] - Starting January 1, 2025, a new management system for medical insurance payment qualifications will be implemented, introducing a point-based system for violations to ensure the safety of medical insurance funds [7] Research and Development - Researchers at Kunming University of Science and Technology have successfully constructed an in vitro model of the stomach, providing a new platform for studying human gastric organ development [8] Public Sentiment Alerts - Zhejiang Pharmaceutical announced that its shareholder, Guotou Gaoke, plans to reduce its stake by up to 1% within three months, which will not affect the company's control [9]

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-112 江苏吴中医药发展股份有限公司 关于盐酸林可霉素注射液通过仿制药一致性评价的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实、准确和完整承担个别及连带责任。 近日，江苏吴中医药发展股份有限公司（以下简称"公司"）全资子公司江苏吴中医药集团有限公司下属 分支机构江苏吴中医药集团有限公司苏州制药厂（以下简称"苏州制药厂"）收到了国家药品监督管理局 （以下简称"国家药监局"）核准签发的关于"盐酸林可霉素注射液"（以下简称"该药品"或"本品"）的 《药品补充申请批准通知书》（通知书编号：2025B04321），该药品通过仿制药质量和疗效一致性评 价（以下简称"仿制药一致性评价"）。现将相关情况公告如下： 一、药品基本情况 二、药品的其他相关情况 药品名称：盐酸林可霉素注射液 剂型：注射剂 规格：2ml：0.6g（按C18H34N2O6S计） 药品批准文号：国药准字H32021365 注册分类：化学药品 上市许可持有人：江苏吴中医药集团有限公司苏州制药厂 药品生产企业：江苏吴中医药集团有限公 ...

Summary of Key Points Core Viewpoint - The average stock price in the A-share market is 13.50 yuan, with 30 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.46 yuan [1]. Group 1: A-Share Market Overview - As of September 22, the Shanghai Composite Index closed at 3828.58 points, with the average A-share price at 13.50 yuan [1]. - The distribution of high-priced and low-priced stocks is relatively small in the overall A-share market [1]. Group 2: Low-Priced Stocks - There are 30 stocks priced below 2 yuan, with *ST Gao Hong having the lowest price at 0.46 yuan, followed by Zhi Tian Tui and *ST Su Wu at 0.46 yuan and 0.91 yuan respectively [1]. - Among the low-priced stocks, 14 are ST stocks, accounting for 46.67% of the total [1]. Group 3: Low-Priced Stock Rankings - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, and industry classifications [1][2]. - Notable low-priced stocks include *ST Gao Hong (0.46 yuan), *ST Su Wu (0.91 yuan), and *ST Jin Ke (1.41 yuan) [1][2].

公告显示，该品适用于由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染，但仅适用于对青霉 素过敏的患者或经医生判断不宜使用青霉素的患者。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月22日，*ST苏吴发布公告称，公司全资子公司江苏吴中 医药集团有限公司下属分支机构江苏吴中医药集团有限公司苏州制药厂收到了国家药品监督管理局核准 签发的关于"盐酸林可霉素注射液"的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致 性评价。 ...